Bausch + Lomb Corporation (TSX: BLCO)
Market Cap | 6.99B |
Revenue (ttm) | 5.87B |
Net Income (ttm) | -458.77M |
Shares Out | 351.52M |
EPS (ttm) | -1.31 |
PE Ratio | n/a |
Forward PE | 78.74 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,326 |
Open | 20.83 |
Previous Close | 20.76 |
Day's Range | 19.92 - 20.83 |
52-Week Range | 18.11 - 28.96 |
Beta | 0.47 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Jul 31, 2024 |
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and ... [Read more]
News
Bausch + Lomb Announces First-Quarter 2024 Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quar...
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentati...
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Frontiers in O...
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE...
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter...
Bausch + Lomb Stock Jumps After Better-Than-Expected Earnings, Guidance (Investopedia)
A big jump in pharmaceutical sales helped eye-care products maker Bausch + Lomb Corp. beat profit and sales estimates for the fourth quarter.
Eye Care-Focused Bausch + Lomb's Stock Surges On Upbeat Annual Guidance Despite Deeper Losses
Bausch + Lomb Corp (NYSE: BLCO) reported the fourth quarter of 2023 sales of $1.173 billion, up 18% year-on-year (Y/Y), beating the consensus of $1.02 billion . Excluding the unfavorable impact of fo...
Bausch & Lomb's stock soars 11% after earnings beat
Bausch + Lomb Corp.'s stock soared 10% early Wednesday, after the vision-care company's adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024.
Bausch + Lomb Corp at JPMorgan Healthcare Conference Transcript
Bausch + Lomb Corp at JPMorgan Healthcare Conference Transcript
Bausch + Lomb Corp at Morgan Stanley Global Healthcare Conference Transcript
Bausch + Lomb Corp at Morgan Stanley Global Healthcare Conference Transcript
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month
Eye health products company Bausch + Lomb Corp (NYSE: BLCO) is scheduled to release its fourth-quarter and full-year 2023 financial results on February 21, 2024. According to data from Benzinga Pro ,...
Bausch + Lomb (BLCO) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Stree...
Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Bausch + Lomb (BLCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Bausch + Lomb (BLCO) Stock?
Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.
Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman ...
Bausch + Lomb (BLCO) Beats Q2 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.29 per share a year ago.
BLCO or DOCS: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with Bausch + Lomb (BLCO) and Doximity (DOCS). But which of these two stocks is more attractive to value investors?
Bausch Health's Bausch + Lomb to Acquire Novartis' XIIDRA(R)
LAVAL, QC / ACCESSWIRE / June 30, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has entered into a definitive agreeme...
20 Stocks That Look Like They're in Bubble Territory Right Now
Stocks that are difficult to sell short are likely to be overvalued, a new study finds. These fit the bill.
Bausch + Lomb (BLCO) Q1 Earnings Lag Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.24 per share a year ago.
Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform
VAUGHAN, Ontario & HEIDELBERG, Germany--(BUSINESS WIRE)--Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, and Heidelberg Engineering, today ann...
Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live bet...
SparingVision appoints Joseph C. Papa as Chairman
SparingVision appoints Jo seph C. Papa as Chairman
Bausch + Lomb beats Q4 profit and revenue estimates
Bausch + Lomb Corp. BLCO, -2.01% said Wednesday it had a loss of $1 million, or breakeven on a per-share basis, for the fourth quarter, after earnings of $51 million, or 15 cents a share, in the year-...
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see be...